Partial
Partially Aligned
Patient Risk:
Low
Summary
The claim is generally consistent with the label identifying mitomycin as the active ingredient in an oncology product, but the provided label excerpts do not explicitly state that mitomycin is used in chemotherapy.
Category Scores
Accurate Statements
Mitomycin is a drug used in chemotherapy.
No explicit support in the provided prescribing-information excerpts. The excerpts provided only include sections on JELMYTO indications, administration route, contraindications, warnings/precautions, adverse reactions, and pregnancy-related statements; they do not explicitly use the term 'chemotherapy' or state the drug is used in chemotherapy.
Unsupported Statements
Mitomycin is a drug used in chemotherapy.
The supplied FDA label excerpts do not explicitly state that mitomycin is used in chemotherapy (they describe JELMYTO for LG-UTUC and mitomycin as the active ingredient, but do not use/confirm the 'chemotherapy' framing).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is broad and does not include dosing, route, contraindications, or safety guidance; it is not directly actionable based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Claim uses an unsupported general descriptor ('chemotherapy') not explicitly stated in the provided label excerpts.
Suggested Improvement
Rephrase to align with the label excerpts, e.g., reference that JELMYTO (mitomycin) is indicated for treatment of adult patients with low-grade upper tract urothelial cancer, without stating it is 'used in chemotherapy' unless that wording appears in the label.